18
dec
Pipeline Therapeutics Completes $30 Million Series B Financing
Proceeds to advance PIPE-505 in hearing loss and additional neuroregenerative programs focused on synaptogenesis, remyelination and axonal repair
RBV Capital is a dedicated life sciences venture capital fund established in 2014 investing into innovative biomedical projects globally
At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
News
5
dec
RBV Capital announces an exit from another project, returning the full investment amount to its limited partners
In 2017, RBV Capital acquired an equity stake in an innovative UK-based company developing an asset for treating symptoms of multiple sclerosis
5
dec
IAG & Takeda Partner in Ulcerative Colitis Histopathological Image Analysis
Image Analysis Group (“IAG”).today announced a partnership in the field of ulcerative colitis (UC) histopathological image analysis with Takeda Pharmaceutical Company Limited (“Takeda”).